Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.61 |
| ▸ | NPY1R | P25929 | 10/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.61 |
| ▸ | NPY2R | P49146 | 6/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649760 | 1.00 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29611423 | 0.97 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29779431 | 0.95 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL30331385 | 0.93 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29839246 | 0.93 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29450696 | 0.93 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29602482 | 0.92 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL31233596 | 0.92 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| Thymopentin SCHEMBL7498758 | 0.91 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| Thymopentin SCHEMBL989519 | 0.91 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2ROPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | Capacity Bio, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4469805-A1 | COVID-19 THERANOSTIC | Université Libre de Bruxelles (BE) | 2024-12-04 | — | — | EP | disclosed |
| EP-4284779-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023144281-A1 | COVID-19 THERANOSTIC | Université Libre de Bruxelles (BE) | 2023-08-03 | — | — | WO | disclosed |
| WO-2022165189-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. | 2022-07-28 | — | — | US | disclosed |
| US-11331368-B2 | Angiotensin receptor agonists and uses thereof | MONASH UNIVERSITY (AU) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | NLN, MAVS, PINK1 | NPY4R 295/4885NPY1R 176/4885NPY5R 334/4885 |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | NLN, MAVS, PINK1 | NPY4R 295/4885NPY1R 176/4885NPY5R 334/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | NPY4R 1830/4885NPY1R 504/4885NPY5R 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.